You are here: Industry Insights > sintilimab

News List

Innovent and Lilly Jointly Announce the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with Gemcitabine and Platinum Chemotherapy as First-Line Therapy for People with Squamous No prnasia
June 04, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Eli Lilly and Company jointly ...
U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer prnasia
May 18, 2021
Innovent Biologics, Inc. and Eli Lilly and Company today jointly announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for sintilimab injection in combination with pemetrexed and platinum ...
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Therapy for Nonsquamous Non-Small prnasia
February 03, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Eli Lilly and Company, today ...
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab as Second-Line Therapy for Squamous Non-Small Cell Lung Cancer prnasia
January 12, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced with Eli Lilly and ...
Sintilimab Expected to Break the “Iron Triangle” to Become the Fourth Major Immunotherapy for Esophagus Cancer in China PharmaSources/Yefenghong
July 06, 2020
A clinical trial has been conducted to use the Chinese-produced sintilimab as a second-line therapy for advanced ESCC and has achieved positive results.
Sales of Toripalimab and Sintilimab Both Exceeded RMB300 Million PharmaSources/Xiaoyaowan
October 24, 2019
Junshi Biosciences’ toripalimab and Innovent’s sintilimab were successively approved in Dec. 2018, to become the first Chinese-produced anti-PD-1 monoclonal antibodies marketed.

Previous page 1 2 Next page